4D Molecular Therapeutics FDMT Revenue
Revenue at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is 4D Molecular Therapeutics's revenue?
- 4D Molecular Therapeutics (FDMT) reported revenue of $3.05M in Q1 2026.
- How has 4D Molecular Therapeutics's revenue changed year-over-year?
- 4D Molecular Therapeutics's revenue increased by 21664.3% year-over-year, from $14K to $3.05M.
- What is the long-term trend for 4D Molecular Therapeutics's revenue?
- Over 4 years (2021 to 2025), 4D Molecular Therapeutics's revenue has grown at a 47.4% compound annual growth rate (CAGR), from $18.04M to $85.21M.